You are here: Industry Insights > SARS-CoV-2

News List

Long COVID, Big Bills: Grim Legacy of Even Short Hospital Stays drugs
August 26, 2021
When COVID-19 patients are discharged from the hospital, most are far from being well -- even if their hospital stay was fairly short.
SARS-CoV-2 Vaccine Effectiveness 66 Percent During Delta Predominance drugs
August 26, 2021
The vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection decreased to 66 percent when the delta variant became predominant, according to research published in the Aug. 24 early-release issue of the U.S.
CPhI Monthly Podcast: The opportunities and challenges of providing fill and finish services for mRNA platforms cphi-online
August 23, 2021
mRNA (Messenger ribonucleuc acid) technology has been thrust into the limelight in recent months, with the platform proving to be the springboard for two approved vaccines against the SARS-CoV-2 virus.
Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine drugs
August 20, 2021
We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of C firstwordpharma
August 20, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain .
Integral Molecular's Extensive Collection of SARS-CoV-2 Reporter Virus Variants Supports the Clinical Development of Vaccines and MAbs Against Coronavirus prnewswire
August 19, 2021
To aid in the clinical development of new vaccines and monoclonal antibodies (MAbs) effective against emerging and highly infectious coronavirus variants, Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus
Flu Vaccine May Protect Against Adverse Events After SARS-CoV-2 August 18, 2021
Influenza vaccination has a potential protective effect against adverse events within 120 days of a positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) diagnosis, according to a study published online Aug. 3 in PLOS ONE.
NIH hamster study evaluates airborne and fomite transmission of SARS-CoV-2 firstwordpharma
August 18, 2021
National Institutes of Health scientists studying SARS-CoV-2, the virus that causes COVID-19, have defined in Syrian hamsters how different routes of virus exposure are linked to disease severity.
Steelcase teams up with Kontrol Technologies to provide air quality monitoring and viral detection technology prnewswire
August 17, 2021
Steelcase (NYSE: SCS) today announces an exclusive agreement with Kontrol Technologies Corp. (NEO: KNR) (OTCQB: KNRLF) ("Kontrol" or the "Company") to offer customers in the U.S. and Canada access to Kontrol BioCloud® viral detection technology.
Problems in thinking and attention linked to COVID-19 infection worldpharmanews
August 13, 2021
The research found that those with more severe COVID-19 symptoms scored lower on an online series of tests, with performance on reasoning and problem-solving tasks being most affected.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page